Login to Your Account



Clinical Hold On Dyax Drug Sends Shares Into Tailspin

By Randall Osborne


Wednesday, May 26, 2004
About one month ahead of disclosing Phase II data for DX-88 in hereditary angioedema, Dyax Corp. said the FDA has placed the compound on clinical hold pending answers to the agency's questions regarding animal studies. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription